The oncology congress is organised by the N.N. Blokhin National Medical Research Centre of Oncology and the Russian Society of Clinical Oncology (RUSSCO) together with the Association of Oncologists of Russia.

Pharmasyntez, having a wide range of antineoplastic drugs, has been a partner of the congress for many years.

The company’s product portfolio already consists of more than 40 drugs of the cytostatic group, 99% of which are in the list of vital and essential drugs (VED) of the Ministry of Healthcare of Russia. A significant expansion of the range of antineoplastic drugs is expected to happen next year with the company’s launch of the 2nd phase of Pharmasyntez-Nord plant in St. Petersburg, which will increase the production capacity by 8.5 times.

Pharmasyntez-Nord is intending to become one of the leaders of the Russian pharmaceutical industry in terms of wide range of anticancer drugs.